A Phase 1 interventional study of Atropine Sulfate in Myopia, sponsored by Laboratorios Sophia S.A de C.V.. Withdrawn. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 54th largest by enrollment, is one of 8 that started in 2023, is one of 8 in phase 1, and was the 29th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 8 started in 2023.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
Laboratorios Sophia S.A de C.V. has 3 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I Study to evaluate safety and tolerability of PRO-230 (atropine sulphate 0.05%) ophthalmic solution through evaluation of incidence of non-expected adverse events (AE), photophobia, pupillary diameter, incidence of expected adverse events, and best near corrected visual acuity (BNCVA)
A total of 29 healthy volunteers will apply PRO-230 ocular solution on both eyes QD (one time per day) for 14 days. The safety variables will include non expected AE, pupillary diameter and expected AE; tolerability variables will include incidence of photofobia, and BNCVA. Exploratory variables include best corrected visual acuity (BCVA), intraocular pressure (IOP), corneal an conjunctival staining with fluorescein and lissamine green, vital signs (heart rate and blood pressure), and results of the Ocular Confort Index (OCI) questionnaire.
The presence of non-expected AE \< 10% will deem PRO-230 as safe; while an incidence of photophobia \< 30% will deem PRO-230 as tolerable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers will apply one drop of PRO-230 ophthalmic solution (atropine sulphate) on both eyes, QD (one time per day) for 14 days.
Drug: Atropine Sulfate
Atropine Sulfate 0.05% Ophthalmic Solution
Incidence of unexpected adverse events
The number of adverse events presented that are not previously described / known for the active substance in this pharmaceutic form and concentration.
Time frame: Through Day 21 ± 1 (Safety Call)
Incidence of photophobia
The number of cases of photophobia.
Time frame: Through Day 21 ± 1 (Safety Call)
Pupillary Diameter
Change of pupillary diameter after exposure to the investigation product.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)]
Incidence of expected adverse events
The number of adverse events presented that are previously described / known for the active substance in this pharmaceutic form and concentration.
Time frame: Through Day 21 ± 1 (Safety Call)
Measurement of the change in best near corrected visual acuity (BNCVA)
The change in BNCVA after exposure to investigation product, compared to basal value.
Time frame: Time Frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Measurement of the change in best corrected visual acuity (BCVA)
The change in BCVA after exposure to investigation product, compared to basal value.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Changes in intraocular pressure (IOP)
The change in IOP after exposure to investigation product, compared to basal value.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Incidence of corneal and conjunctival staining
Presence of corneal and conjunctival staining with fluorescein and lissamine green after exposure to investigation product.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)]
Measurement of vital signs (blood pressure)
The change in blood pressure after exposure to investigation product, compared to basal value.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Measurement of vital signs (heart rate)
The change in heart rate after exposure to investigation product, compared to basal value.
Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Value of the ocular comfort index (OCI) questionnaire
The change ocular comfort index (OCI) questionnaire results after exposure to investigation product, compared to basal value.
Time frame: Days: 1 (Basal Visit), 16 ± 1 (Final Visit)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2023; primary completion for Mar 2023, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine
Laboratorios Sophia S.A de C.V. →